secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001104659-25-074987
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q2 net loss $36.1M; positive sevasemten data in Becker, Duchenne
-------------------------------------------------------------------------

- Net loss of $36.1M ($0.34/share) for Q2 2025; cash and equivalents $594M as of June 30.
- MESA trial data: 99% enrollment; NSAA scores stable over 18 months in Becker participants.
- Phase 2 LYNX/FOX trials in Duchenne identify 10 mg sevasemten dose for Phase 3; FDA meeting planned Q4 2025.
- CIRRUS-HCM (EDG-7500) trial advancing; Part D enrolling; update expected Q4 2025.
- GRAND CANYON pivotal trial in Becker fully enrolled; topline data expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/0001104659-25-074987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/tm2522645d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer